Management and Prevention of Thrombocytopenia Supportive Care


Nplate Produces Rapid Response in Adults with ITP (December 20, 2011)

Among adults with low platelet counts or bleeding symptoms from primary immune thrombocytopenia (ITP), treatment with Nplate® (romiplostim) produces a rapid increase in platelet counts. These results... Continue Reading

Nplate Active for More than Five Years in Adults with Chronic ITP (December 13, 2010)

Nplate® (romiplostim) appears to maintain platelet counts among adult patients with chronic immune (idiopathic) thrombocytopenia purpura (ITP) for more than five years. These results were presented at... Continue Reading

Nplate Reduces Treatment Failure and Splenectomy in Patients with ITP (November 17, 2010)

Compared with standard therapies, Nplate® (romiplostim) appears to reduce the risk of treatment failure and need for splenectomy among adult patients with chronic immune thrombocytopenia (ITP). These... Continue Reading

Nplate Evaluated in Children with Chronic ITP (December 8, 2009)

Among children with chronic immune thrombocytopenic purpura (ITP; an autoimmune disorder characterized by low platelet counts), treatment with Nplate® (romiplostim) stimulates platelet production and... Continue Reading

Nplate® Approved for Thrombocytopenia in Patients with ITP (August 25, 2008)

Nplate® Approved for Thrombocytopenia in Patients with ITP The U.S. Food and Drug Administration (FDA) has approved the use of Nplate® (romiplostim) for the treatment of thrombocytopenia in adult patients... Continue Reading

Romiplostim Improves Low Platelet Levels (January 2, 2008)

According to results recently presented at the 2007 annual meeting of the American Society of Hematology (ASH), the investigative agent romiplostim (AMG531) continues to significantly improve platelet... Continue Reading

Myelosuppression: A Report from the 2007 International MASCC/ISOO Symposium (November 5, 2007)

Myelosuppression: A Report from the 2007 International MASCC/ISOO Symposium Introduction At the 2007, 20th Anniversary International MASCC/ISOO Symposium, neutropenia, thrombocytopenia, and anemia remained... Continue Reading

Updates in the Management of Thrombocytopenia: A Report from the 2007 ONS Annual Congress (October 15, 2007)

Updates in the Management of Thrombocytopenia: A Report from the 2007 ONS Annual Congress At the 2007 annual meeting of the Oncology Nursing Society (ONS), several aspects of managing thrombocytopenia... Continue Reading

Myelosuppression: A Report from the 2007 ONS Annual Congress (October 15, 2007)

Myelosuppression: A Report from the 2007 ONS Annual Congress Introduction Myelosuppression was an important topic at the 2007 Oncology Nursing Society Congress. Two satellite symposia, two instructional... Continue Reading

Updates on the Management of Hematopoietic Supportive Care – ASCO 2007 (October 12, 2007)

Updates on the Management of Hematopoietic Supportive Care – ASCO 2007 Introduction Chemotherapy induced alterations on bone marrow function, including myelosuppression, anemia, and thrombocytopenia,... Continue Reading

AMG 531 May Be Effective in Treating Thrombocytopenia in Patients with MDS (June 13, 2007)

AMG 531 May Be Effective in Treating Thrombocytopenia in Patients with MDS According to results recently presented at the 2007 annual meeting of the American Society of Clinical Oncology (ASCO), the... Continue Reading

Cryopreserved Platelets Effective for Platelet Transfusions (July 1, 2002)

Cryopreserved Platelets Effective for Platelet Transfusions According to a recent article published in The Lancet, a newly developed storage solution allows for safe and effective administration... Continue Reading

Thrombopoietin Decreases Platelet Transfusions (February 25, 2002)

Thrombopoietin Decreases Platelet Transfusions The use of pegylated recombinant human megakaryocyte growth and development factor, or PEG-rHuMGDF, appears to increase platelet levels and thus delay... Continue Reading

Interleukin-11 improves platelet recovery and reduces the need for platelet transfusions in patients treated with chemotherapy. (February 25, 2002)

Interleukin-11 improves platelet recovery and reduces the need for platelet transfusions in patients treated with chemotherapy. Bone marrow suppression, a delay in the ability of the bone marrow to... Continue Reading

Interleukin-11 is the first platelet blood cell growth factor approved by the Food and Drug Administration. Interleukin-11 is demonstrated to decrease platelet transfusion requirements in patients wit (February 25, 2002)

Interleukin-11 is the first platelet blood cell growth factor approved by the Food and Drug Administration. Interleukin-11 is demonstrated to decrease platelet transfusion requirements in patients with... Continue Reading

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS